Ticagrelor is a drug with antiplatelet effect, circulated in Vietnam under the brand name Brilinta. In the fourth quarter of 2020, the US Food and Drug Administration (FDA) approved Brilinta to be prescribed for the purpose of reducing the risk of stroke in patients with ischemic stroke (with NISSH score <=5) or stroke. high-risk transient ischemic attack.

Acute stroke often causes many stroke sequelae that greatly affect the health and life of the patient. Reduced vascular endurance or reduced cardiopulmonary endurance after stroke is one of the sequelae that often appears in patients. Read the article below to learn more about reduced endurance after stroke and some rehabilitation measures for this problem.